CB Therapeutics, a U.S.-based synthetic biology company known for its innovative bio-manufacturing solutions, today announced the expansion of its platform to include ergoline-based compounds.

By contrast, CB Therapeutics utilizes yeast-based precision fermentation to produce bioidentical ergoline compounds with minimal waste, reduced carbon footprint, and dependable yields at any scale.